SQLite Web: event_store.db

Update row 129912 in events

seq

Primary key. INTEGER

id

TEXT NOT NULL

kind

TEXT NOT NULL

ts

TEXT NOT NULL

actor

TEXT

subject_entity_ids

TEXT

payload

{"created_at":"2026-04-18T03:05:05.644967+00:00","dedupe_key":"signal_enriched:discovery_sec_filing_delta:6b05ac5af91e0fa1","evidence_event_ids":["evt_226fe37e9bdf"],"signal_type":"discovery_sec_filing_delta","source":"discovery_sec_filings","value":{"aggregator_url":"https://www.sec.gov/Archives/edgar/data/1783328/0001193125-26-160304.txt","as_of":"2026-04-18T03:05:05.644967+00:00","canonical_url":"https://www.sec.gov/Archives/edgar/data/1783328/0001193125-26-160304.txt","company":"TScan Therapeutics, Inc.","enrichment":{"aggregator_url":"https://www.sec.gov/Archives/edgar/data/1783328/0001193125-26-160304.txt","article_chars":5000,"article_truncated":true,"blocked_reason":null,"candidate_id":"sc_fb186b0249a5f62d","canonical_host":"sec.gov","canonical_is_aggregator":false,"canonical_url":"https://www.sec.gov/Archives/edgar/data/1783328/0001193125-26-160304.txt","content_type":"text/plain","enriched_at":"2026-04-18T03:34:25.470299+00:00","extraction_method":"trafilatura","fetched_description":"","fetched_title":"DEF 14A","final_url":"https://www.sec.gov/Archives/edgar/data/1783328/0001193125-26-160304.txt","html_truncated":true,"paywall_likely":false,"publisher_domain":"sec.gov","publisher_resolution":"canonical_url","requested_url":"https://www.sec.gov/Archives/edgar/data/1783328/0001193125-26-160304.txt","source_event_id":"evt_226fe37e9bdf","source_quality":"high","status_code":200,"version":"signal_enrichment_v2"},"form_type":"DEF 14A","fp":"4fa0cd827ccdb537","kind":"sec_filing","published_at":"20260417","publisher_domain":"sec.gov","signal_understanding":{"analysis_basis":"article","claim_confidence":0.78,"dates_mentioned":["2026-04-15","2026-04-17","2026-05-20","2026-04-18"],"entities":[{"asset_class":"equity","name":"TScan Therapeutics, Inc.","relevance":"high","symbol":"TCRX","type":"issuer"},{"asset_class":"other","name":"Securities and Exchange Commission (SEC)","relevance":"medium","symbol":"","type":"regulator"},{"asset_class":"other","name":"VirtualShareholderMeeting.com","relevance":"medium","symbol":"","type":"meeting_platform"},{"asset_class":"other","name":"ProxyVote.com","relevance":"medium","symbol":"","type":"voting_platform"}],"event_type":"listing","information_gaps":["What changed vs prior known state is not provided in the signal; no prior filing/version details are included to compare deltas.","The specific independent registered public accounting firm name is not included in the provided text excerpt.","The exact number by which authorized voting common shares will be increased is not included in the provided text excerpt.","Details of the two Class II director nominees are not included in the provided text excerpt.","The filing_date field in the deterministic context (2026-04-18T03:05:05.644967+00:00) is not explicitly stated in the article text excerpt; it is only present in the provided structured context."],"key_facts":["The proxy statement is for TScan Therapeutics, Inc.\u2019s 2026 Annual Meeting of Stockholders.","The Annual Meeting will be held online on May 20, 2026 at 8:30 a.m. Eastern Time.","Stockholders of record at the close of business on April 15, 2026 are entitled to notice and to vote.","The board recommends voting \u201cFOR\u201d (1) election of each of two nominees for Class II director, (2) ratification of the appointment of the independent registered public accounting firm for the fiscal year ending December 31, 2026, (3) approval of an amendment to the Amended and Restated Certificate of Incorporation to increase the number of authorized shares of voting common stock, and (4) approval of an adjournment if necessary to solicit additional proxies.","The proxy statement is dated April 17, 2026 and is first being mailed to stockholders on or about April 17, 2026.","The company will use the full set delivery option under Rule 14a-16(n), delivering proxy statement, proxy card, and the 2025 Annual Report on Form 10-K by mail and posting proxy materials on a publicly accessible website.","Voting methods described include voting online (www.proxyvote.com), by telephone (1-800-690-6903), or by returning the proxy card; a 16-digit control number is required for online/telephone attendance/voting.","The proxy is revocable in accordance with procedures set forth in the proxy statement (details not included in provided text)."],"numeric_claims":[{"label":"Annual Meeting date","value":"May 20, 2026"},{"label":"Annual Meeting time (ET)","value":"8:30 a.m."},{"label":"Record date","value":"April 15, 2026"},{"label":"Proxy statement date","value":"April 17, 2026"},{"label":"Control number length","value":"16-digit"},{"label":"Telephone voting number","value":"1-800-690-6903"}],"primary_claim":"TScan Therapeutics, Inc. filed Form DEF 14A for its 2026 Annual Meeting of Stockholders to be held May 20, 2026.","relevance_score":0.62,"sentiment":"neutral","source_quality":"high","summary":"TScan Therapeutics, Inc. filed a DEF 14A proxy statement for its 2026 Annual Meeting of Stockholders. The filing includes proposals to elect Class II directors, ratify the independent auditor, amend the charter to increase authorized voting common shares, and allow adjournment if needed.","topics":["SEC filing","DEF 14A","proxy statement","annual meeting","corporate governance","auditor ratification","charter amendment","authorized shares"]},"source":"sec_edgar","source_domain":"sec.gov","summary":"Form DEF 14A \u00b7 TScan Therapeutics, Inc. \u00b7 Filed 20260417","ticker":"TCRX","tickers":["TCRX"],"title":"TCRX filed DEF 14A","url":"https://www.sec.gov/Archives/edgar/data/1783328/0001193125-26-160304.txt"}}

TEXT NOT NULL

source_ref

TEXT

confidence

REAL (default 0.0

dedupe_key

TEXT

episode_id

TEXT

created_at

TEXT NOT NULL (default strftime('%Y-%m-%dT%H:%M:%fZ','now')

Cancel